Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 4Uveal Melanoma 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Osteosarcoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

tocilizumab 1pembrolizumab 1abexinostat 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Ipilimumab 1Immunotherapy 1Immunoglobulin G 1Drug Therapy 1Disulfides 1CTLA-4 Antigen 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ureteral Neoplasms × tocilizumab × Dermatologic × Clear all
NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
35 enrolled
DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡